Antibody Correlates of Protection from Clinical Malaria in an Area of Low and Unstable Malaria Transmission

Overview

Journal Am J Trop Med Hyg

Specialty Tropical Medicine

Date 2020 Oct 30

PMID 33124533

Citations 9

Authors

Karen E S Hamre

Bartholomew N Ondigo

James S Hodges

Sheetij Dutta

Michael Theisen

George Ayodo

Chandy C John

Affiliations

Soon will be listed here.

Abstract

Immune correlates of protection against clinical malaria are difficult to ascertain in low-transmission areas because of the limited number of malaria cases. We collected blood samples from 5,753 individuals in a Kenyan highland area, ascertained malaria incidence in this population over the next 6 years, and then compared antibody responses to 11 vaccine candidate antigens in individuals who did versus did not develop clinical malaria in a nested case-control study (154 cases and 462 controls). Individuals were matched by age and village. Antigens tested included circumsporozoite protein (CSP), liver-stage antigen (LSA)-1, apical membrane antigen-1 FVO and 3D7 strains, erythrocyte-binding antigen-175, erythrocyte-binding protein-2, merozoite surface protein (MSP)-1 FVO and 3D7 strains, MSP-3, and glutamate-rich protein (GLURP) N-terminal non-repetitive (R0) and C-terminal repetitive (R2) regions. After adjustment for potential confounding factors, the presence of antibodies to LSA-1, GLURP-R2, or GLURP-R0 was associated with decreased odds of developing clinical malaria (odds ratio [OR], [95% CI] 0.56 [0.36-0.89], 0.56 [0.36-0.87], and 0.77 [0.43-1.02], respectively). Levels of antibodies to LSA-1, GLURP-R2, and CSP were associated with decreased odds of developing clinical malaria (OR [95% CI]; 0.61 [0.41-0.89], 0.60 [0.43-0.84], and 0.49 [0.24-0.99], for every 10-fold increase in antibody levels, respectively). The presence of antibodies to CSP, GLURP-R0, GLURP-R2, and LSA-1 combined best-predicted protection from clinical malaria. Antibodies to CSP, GLURP-R0, GLURP-R2, and LSA-1 are associated with protection against clinical malaria in a low-transmission setting. Vaccines containing these antigens should be evaluated in low malaria transmission areas.

Citing Articles

Antibody correlates of risk of clinical malaria in an area of low and unstable malaria transmission in western Kenya.

Odhiambo E, Mellencamp K, Ondigo B, Hamre K, Beeson J, Opi D Malar J. 2025; 24(1):73.

PMID: 40033373 PMC: 11877692. DOI: 10.1186/s12936-025-05300-1.

The impact of intermittent preventive treatment in school aged children with dihydroartemisinin piperaquine and artesunate amodiaquine on IgG response against six blood stage Plasmodium falciparum antigens.

Lyimo E, Makenga G, Turner L, Lavstsen T, Lusingu J, Van Geertruyden J PLoS One. 2025; 20(1):e0316482.

PMID: 39883707 PMC: 11781616. DOI: 10.1371/journal.pone.0316482.

Antibody-Dependent Respiratory Burst against Merozoites in Individuals Living in an Area with Declining Malaria Transmission.

Mutemi D, Tuju J, Ogwang R, Nyamako L, Wambui K, Cruz I Vaccines (Basel). 2024; 12(2).

PMID: 38400186 PMC: 10892224. DOI: 10.3390/vaccines12020203.

Cytolytic circumsporozoite-specific memory CD4 T cell clones are expanded during Plasmodium falciparum infection.

Furtado R, Paul M, Zhang J, Sung J, Karell P, Kim R Nat Commun. 2023; 14(1):7726.

PMID: 38001069 PMC: 10673885. DOI: 10.1038/s41467-023-43376-y.

Host-parasite interactions during infection: Implications for immunotherapies.

Chandley P, Ranjan R, Kumar S, Rohatgi S Front Immunol. 2023; 13:1091961.

PMID: 36685595 PMC: 9845897. DOI: 10.3389/fimmu.2022.1091961.

References

McCarra M, Ayodo G, Sumba P, Kazura J, Moormann A, Narum D . Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria. Pediatr Infect Dis J. 2011; 30(12):1037-42. PMC: 3222715. DOI: 10.1097/INF.0b013e31822d1451. View

Mutanda A, Cheruiyot P, Hodges J, Ayodo G, Odero W, John C . Sensitivity of fever for diagnosis of clinical malaria in a Kenyan area of unstable, low malaria transmission. Malar J. 2014; 13:163. PMC: 4021053. DOI: 10.1186/1475-2875-13-163. View

Cummings J, Spring M, Schwenk R, Ockenhouse C, Kester K, Polhemus M . Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine. 2009; 28(31):5135-44. DOI: 10.1016/j.vaccine.2009.08.046. View

Osier F, Fegan G, Polley S, Murungi L, Verra F, Tetteh K . Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun. 2008; 76(5):2240-8. PMC: 2346713. DOI: 10.1128/IAI.01585-07. View

Jepsen M, Jogdand P, Singh S, Esen M, Christiansen M, Issifou S . The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas. J Infect Dis. 2013; 208(3):479-88. DOI: 10.1093/infdis/jit185. View

Steketee R, Campbell C . Impact of national malaria control scale-up programmes in Africa: magnitude and attribution of effects. Malar J. 2010; 9:299. PMC: 2988827. DOI: 10.1186/1475-2875-9-299. View

Soe S, Theisen M, Roussilhon C, Aye K, Druilhe P . Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich.... Infect Immun. 2003; 72(1):247-52. PMC: 343946. DOI: 10.1128/IAI.72.1.247-252.2004. View

Dziegiel M, Rowe P, Bennett S, Allen S, Olerup O, Gottschau A . Immunoglobulin M and G antibody responses to Plasmodium falciparum glutamate-rich protein: correlation with clinical immunity in Gambian children. Infect Immun. 1993; 61(1):103-8. PMC: 302693. DOI: 10.1128/iai.61.1.103-108.1993. View

Bejon P, White M, Olotu A, Bojang K, Lusingu J, Salim N . Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis. 2013; 13(4):319-27. PMC: 3771416. DOI: 10.1016/S1473-3099(13)70005-7. View

10.

Cohen S, Butcher G, CRANDALL R . Action of malarial antibody in vitro. Nature. 1969; 223(5204):368-71. DOI: 10.1038/223368a0. View

11.

Barnes K, Durrheim D, Little F, Jackson A, Mehta U, Allen E . Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med. 2005; 2(11):e330. PMC: 1240068. DOI: 10.1371/journal.pmed.0020330. View

12.

Hoffman S, Oster C, Plowe C, Woollett G, Beier J, Chulay J . Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science. 1987; 237(4815):639-42. DOI: 10.1126/science.3299709. View

13.

Iriemenam N, Khirelsied A, Nasr A, ElGhazali G, Giha H, Elhassan A-Elgadir T . Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. Vaccine. 2008; 27(1):62-71. DOI: 10.1016/j.vaccine.2008.10.025. View

14.

Zhou Z, Xiao L, Branch O, Kariuki S, Nahlen B, Lal A . Antibody responses to repetitive epitopes of the circumsporozoite protein, liver stage antigen-1, and merozoite surface protein-2 in infants residing in a Plasmodium falciparum-hyperendemic area of western Kenya. XIII. Asembo Bay Cohort Project. Am J Trop Med Hyg. 2002; 66(1):7-12. DOI: 10.4269/ajtmh.2002.66.7. View

15.

Lusingu J, Vestergaard L, Alifrangis M, Mmbando B, Theisen M, Kitua A . Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission. Malar J. 2005; 4:48. PMC: 1262760. DOI: 10.1186/1475-2875-4-48. View

16.

Polley S, Tetteh K, Lloyd J, Akpogheneta O, Greenwood B, Bojang K . Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis. 2006; 195(2):279-87. DOI: 10.1086/509806. View

17.

Hogh B, Petersen E, Dziegiel M, David K, Hanson A, Borre M . Antibodies to a recombinant glutamate-rich Plasmodium falciparum protein: evidence for protection of individuals living in a holoendemic area of Liberia. Am J Trop Med Hyg. 1992; 46(3):307-13. DOI: 10.4269/ajtmh.1992.46.307. View

18.

Belard S, Issifou S, Hounkpatin A, Schaumburg F, Ngoa U, Esen M . A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children. PLoS One. 2011; 6(7):e22525. PMC: 3145647. DOI: 10.1371/journal.pone.0022525. View

19.

Genton B, Kramer K, Chang S, Hui G, Baisor M, Alpers M . Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity. Am J Trop Med Hyg. 1996; 54(5):443-8. DOI: 10.4269/ajtmh.1996.54.443. View

20.

Dodoo D, Theisen M, Kurtzhals J, Akanmori B, Koram K, Jepsen S . Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis. 2000; 181(3):1202-5. DOI: 10.1086/315341. View